Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALEXANDRIA REAL ESTATE EQUITIES, INC.ARE · Entity 419 | Director · Executive Chairman | September 11, 2026 | September 15, 2026 |
| Applied Therapeutics, Inc.APLT · Entity 67708 | Director | June 06, 2024 | June 07, 2024 |
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | Director | March 15, 2019 | March 19, 2019 |
| Korro Bio, Inc.FREQ · Entity 6388 | Director | August 17, 2022 | August 19, 2022 |
| MeiraGTx Holdings plcMGTX · Entity 4734 | Director | June 07, 2022 | June 09, 2022 |
| TRex Bio, Inc.TRXB · Entity 184308 | Director | October 13, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALEXANDRIA REAL ESTATE EQUITIES, INC.
Report date September 11, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 597,724 |
Reported balance
After 2026-09-11 transaction · row 1
1 source rowRow 1 · 2026-09-11 · Purchase · Acquired 5,000 · Balance 597,724 F1: The shares were purchased at prices ranging from $49.38 to $49.82. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were purchased at prices ranging from $49.38 to $49.82. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Applied Therapeutics, Inc.
Report date June 06, 2024 · Filed June 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 498,414 |
Reported balance
After 2024-06-06 transaction · row 1
1 source rowRow 1 · 2024-06-06 · Grant · Acquired 45,000 · Balance 498,414 F1: Consists of compensatory Restricted Stock Units granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. One-fourth (1/4th) of the Restricted Stock Units shall vest on a quarterly basis from June 6, 2024 until the earlier of (i) the first anniversary of the date of grant and (ii) the date of the issuer's next annual stockholder meeting, in each case, subject to the reporting person's continuous service as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of compensatory Restricted Stock Units granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. One-fourth (1/4th) of the Restricted Stock Units shall vest on a quarterly basis from June 6, 2024 until the earlier of (i) the first anniversary of the date of grant and (ii) the date of the issuer's next annual stockholder meeting, in each case, subject to the reporting person's continuous service as of each such date.
Atara Biotherapeutics, Inc.
Report date March 15, 2019 · Filed March 19, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 888,355 |
Reported balance
After 2019-03-15 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-03-15 · Sale · Disposed 20,000 · Balance 888,355 F1: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.10 to $38.56. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F2: Consists of shares of common stock held by Alexandria Equities, LLC. Mr. Marcus is the Chairman, CEO and Founder of Alexandria Real Estate Equities, Inc., which is the managing member of Alexandria Equities, LLC, which has full voting and investment power with respect to the shares owned by Alexandria Equities, LLC. As an officer of Alexandria Real Estate Equities, Inc., Mr. Marcus may be deemed to have voting and investment power with respect to the shares owned by Alexandria Equities, LLC. Mr. Marcus disclaims beneficial ownership of the shares held by Alexandria Equities, LLC, except to the extent of his underlying pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectHeld by the Joel S. Marcus and Barbara A. Marcus Family Trust | 4,000 |
Reported balance
Holding disclosure · report date 2019-03-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,000 |
| Common StockSEC Table I · non-derivative | Direct | 7,500 |
Reported balance
Holding disclosure · report date 2019-03-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 7,500 |
Filing footnotes · ownership attribution and instrument terms
F1: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.10 to $38.56. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F2: Consists of shares of common stock held by Alexandria Equities, LLC. Mr. Marcus is the Chairman, CEO and Founder of Alexandria Real Estate Equities, Inc., which is the managing member of Alexandria Equities, LLC, which has full voting and investment power with respect to the shares owned by Alexandria Equities, LLC. As an officer of Alexandria Real Estate Equities, Inc., Mr. Marcus may be deemed to have voting and investment power with respect to the shares owned by Alexandria Equities, LLC. Mr. Marcus disclaims beneficial ownership of the shares held by Alexandria Equities, LLC, except to the extent of his underlying pecuniary interest therein.
Korro Bio, Inc.
Report date August 17, 2022 · Filed August 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2030-06-10 | Direct | 14,846 |
Reported balance
After 2022-08-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-08-17 · Grant · Acquired 14,846 · Balance 14,846 F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F1: The option vested in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $18.63 · Expires 2030-06-10 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-08-17 · Disposition to issuer · Disposed 14,846 · Balance 0 F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F3: The option vests in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2031-06-16 | Direct | 14,846 |
Reported balance
After 2022-08-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-08-17 · Grant · Acquired 14,846 · Balance 14,846 F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F4: The option vested in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.14 · Expires 2031-06-16 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-08-17 · Disposition to issuer · Disposed 14,846 · Balance 0 F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F5: The option vests in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vested in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders
F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options.
F3: The option vests in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders
F4: The option vested in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders.
F5: The option vests in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders.
MeiraGTx Holdings plc
Report date June 07, 2022 · Filed June 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.25 · Expires 2032-06-07 | Direct | 15,000 |
Reported balance
After 2022-06-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-07 · Grant · Acquired 15,000 · Balance 15,000 F1: The option shall vest and become exercisable in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 15,000 |
Reported balance
After 2022-06-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-06-07 · Grant · Acquired 15,000 · Balance 15,000 F2: Each restricted share unit converts into one ordinary share upon vesting. F3: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and become exercisable in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023.
F2: Each restricted share unit converts into one ordinary share upon vesting.
F3: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023.
TRex Bio, Inc.
Report date October 13, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,871 |
Reported balance
After 2026-10-13 transaction · row 1
1 source rowRow 1 · 2026-10-13 · Conversion · Acquired 41,871 · Balance 41,871 F1: On October 13, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 3.8649-to-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-10-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-13 · Conversion · Disposed 161,828 · Balance 0 F1: On October 13, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 3.8649-to-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 13, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 3.8649-to-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Intra-Cellular Therapies, Inc.
Report date April 02, 2025 · Filed April 02, 2025
Section 16 reporting ended · disclosed 2025-04-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 1
1 source rowRow 1 · 2025-04-02 · Disposition to issuer · Disposed 48,238 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and condi-tions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company ("Company Shares") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2025-04-02 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-04-02 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and condi-tions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company ("Company Shares") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings. F3: Represents securities held of record by Alexandria Real Estate Equities, Inc. The reporting person is the Executive Chairman & Founder of Alexandria Real Estate Equities, Inc. and may therefore be deemed to have voting and investment power with respect to the shares owned by Alexandria Real Estate Equities, Inc. The reporting person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.77 · Expires 2034-06-13 | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-04-02 · Disposition to issuer · Disposed 4,322 · Balance 0 F4: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F5: (Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-04-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-04-02 · Disposition to issuer · Disposed 2,951 · Balance 0 F6: Each restricted stock unit (each, a "Company RSU") represented a contingent right to re-ceive one Company Share. F7: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances. F8: Not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and condi-tions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time").
F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company ("Company Shares") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings.
F3: Represents securities held of record by Alexandria Real Estate Equities, Inc. The reporting person is the Executive Chairman & Founder of Alexandria Real Estate Equities, Inc. and may therefore be deemed to have voting and investment power with respect to the shares owned by Alexandria Real Estate Equities, Inc. The reporting person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
F4: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.
F5: (Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration.
F6: Each restricted stock unit (each, a "Company RSU") represented a contingent right to re-ceive one Company Share.
F7: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances.
F8: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2023 Filed Apr 4, 2023 20:53 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | Tax withholdingCommon Stock | 10,015 | $125.59 | $1,257,783.85 |
DisclosureSEC source: 0001035443-23-000149 · wf-form4_168064157617692.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 358,854 F3 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:53 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | Disposition to issuerCommon Stock | 6,507 | $0.00 | $0.00 |
DisclosureSEC source: 0001035443-23-000149 · wf-form4_168064157617692.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 368,869 F1 · shares: Represents the forfeiture of a portion of a restricted stock award previously reported. F2 · balance_after: The number of shares beneficially owned by the reporting person prior to the reported transactions differs from the amount reflected on his most recent Form 4, which amount was overstated by 13,353 shares, representing the net effect of previously unreported transactions effected between 2000 and 2006. These previous unreported transactions were the result of recently discovered administrative errors and not any error by the reporting person. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 21:58 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 9,000 | $168.00 | $1,512,000.00 |
DisclosureSEC source: 0001035443-23-000116 · wf-form4_167597986424585.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 388,729 Read SEC document |
| January 27, 2023 Filed Jan 31, 2023 21:30 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | Tax withholdingCommon Stock | 5,608 | $160.68 | $901,093.44 |
DisclosureSEC source: 0001035443-23-000103 · wf-form4_167520061271620.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 397,729 F1 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 21:25 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | GrantCommon Stock | 24,051 | $0.00 | $0.00 |
DisclosureSEC source: 0001035443-23-000069 · wf-form4_167355871923581.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 403,337 Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:28 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | GrantCommon Stock | 42,260 | $0.00 | $0.00 |
DisclosureSEC source: 0001035443-23-000051 · wf-form4_167295406898882.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 379,286 Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:06 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | SaleCommon Stock | 5,000 | $50.82 | $254,100.00 |
DisclosureSEC source: 0001209191-22-062324 · doc4.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,233 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.81 to $50.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 21:22 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 6,500 | $150.00 | $975,000.00 |
DisclosureSEC source: 0001035443-22-000330 · wf-form4_167105292770977.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,026 Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 21:37 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 2,500 | $152.00 | $380,000.00 |
DisclosureSEC source: 0001035443-22-000325 · wf-form4_167044902671724.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,526 Read SEC document |
| November 07, 2022 Filed Nov 8, 2022 21:12 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | SaleCommon Stock | 5,000 | $52.11 | $260,558.50 |
DisclosureSEC source: 0001209191-22-056091 · doc4.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,233 Read SEC document |
| November 07, 2022 Filed Nov 8, 2022 21:12 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | SaleCommon Stock | 5,000 | $52.49 | $262,464.50 |
DisclosureSEC source: 0001209191-22-056091 · doc4.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,233 Read SEC document |
| September 14, 2022 Filed Sep 17, 2022 01:01 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 4,125 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001209191-22-050425 · doc4.xml · derivative · entry 8 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,375 Underlying: Common Stock · 4,125 shares Expires 2032-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Reflects an initial grant of 16,500 Options granted on June 3, 2022 to directors under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. One-twelfth (1/12th) of the shares subject to the Option shall vest on July 2, 2022 and each month thereafter, subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| September 14, 2022 Filed Sep 17, 2022 01:01 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 16,500 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001209191-22-050425 · doc4.xml · derivative · entry 7 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,500 shares Expires 2031-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These Options are fully vested. Read SEC document |
| September 14, 2022 Filed Sep 17, 2022 01:01 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,230 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001209191-22-050425 · doc4.xml · derivative · entry 6 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,230 shares Expires 2030-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These Options are fully vested. Read SEC document |
| September 14, 2022 Filed Sep 17, 2022 01:01 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 7,389 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001209191-22-050425 · doc4.xml · derivative · entry 5 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,389 shares Expires 2029-05-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These Options are fully vested. Read SEC document |
| September 14, 2022 Filed Sep 17, 2022 01:01 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Exercise / conversionCommon Stock | 4,125 | $1.05 | $4,331.25 |
DisclosureSEC source: 0001209191-22-050425 · doc4.xml · nonDerivative · entry 4 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,039 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 14, 2022 Filed Sep 17, 2022 01:01 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Exercise / conversionCommon Stock | 16,500 | $1.05 | $17,325.00 |
DisclosureSEC source: 0001209191-22-050425 · doc4.xml · nonDerivative · entry 3 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 14, 2022 Filed Sep 17, 2022 01:01 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Exercise / conversionCommon Stock | 10,230 | $1.05 | $10,741.50 |
DisclosureSEC source: 0001209191-22-050425 · doc4.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,414 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 14, 2022 Filed Sep 17, 2022 01:01 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Exercise / conversionCommon Stock | 7,389 | $1.05 | $7,758.45 |
DisclosureSEC source: 0001209191-22-050425 · doc4.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 67,435 shares previously reported as indirectly held through a family trust of which the reporting person and his spouse are trustees. In accordance with SEC guidance with respect to shares held by living trusts, such shares are now included in the shares directly owned by the reporting person. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:08 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Disposition to issuerStock Option · Derivative | 14,846 | Not disclosed Strike: $10.14 | Not disclosed |
DisclosureSEC source: 0001127602-22-021380 · form4.xml · derivative · entry 4 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,846 shares Expires 2031-06-16 F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F5 · derivative.exercise_date: The option vests in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:08 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 14,846 | Not disclosed Strike: $2.14 | Not disclosed |
DisclosureSEC source: 0001127602-22-021380 · form4.xml · derivative · entry 3 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,846 Underlying: Common Stock · 14,846 shares Expires 2031-06-16 F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F4 · derivative.exercise_date: The option vested in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:08 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Disposition to issuerStock Option · Derivative | 14,846 | Not disclosed Strike: $18.63 | Not disclosed |
DisclosureSEC source: 0001127602-22-021380 · form4.xml · derivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,846 shares Expires 2030-06-10 F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F3 · derivative.exercise_date: The option vests in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:08 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 14,846 | Not disclosed Strike: $2.14 | Not disclosed |
DisclosureSEC source: 0001127602-22-021380 · form4.xml · derivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,846 Underlying: Common Stock · 14,846 shares Expires 2030-06-10 F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F1 · derivative.exercise_date: The option vested in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders Read SEC document |
| August 11, 2022 Filed Aug 12, 2022 22:05 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | SaleCommon Stock | 10,000 | $59.22 | $592,200.00 |
DisclosureSEC source: 0001209191-22-045683 · doc4.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,233 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.09 to $59.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| August 02, 2022 Filed Aug 5, 2022 00:39 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 7,389 | Not disclosed Strike: $1.05 | Not disclosed |
DisclosureSEC source: 0001209191-22-044464 · doc4.xml · derivative · entry 8 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,389 Underlying: Common Stock · 7,389 shares Expires 2029-05-12 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F3 · derivative.exercise_date: These Options are fully vested. Read SEC document |
| August 02, 2022 Filed Aug 5, 2022 00:39 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 7,389 | Not disclosed Strike: $10.00 | Not disclosed |
DisclosureSEC source: 0001209191-22-044464 · doc4.xml · derivative · entry 7 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,389 shares Expires 2029-05-12 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F3 · derivative.exercise_date: These Options are fully vested. Read SEC document |
| August 02, 2022 Filed Aug 5, 2022 00:39 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 10,230 | Not disclosed Strike: $1.05 | Not disclosed |
DisclosureSEC source: 0001209191-22-044464 · doc4.xml · derivative · entry 6 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,230 Underlying: Common Stock · 10,230 shares Expires 2030-06-03 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F3 · derivative.exercise_date: These Options are fully vested. Read SEC document |
| August 02, 2022 Filed Aug 5, 2022 00:39 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 10,230 | Not disclosed Strike: $44.02 | Not disclosed |
DisclosureSEC source: 0001209191-22-044464 · doc4.xml · derivative · entry 5 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,230 shares Expires 2030-06-03 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F3 · derivative.exercise_date: These Options are fully vested. Read SEC document |
| August 02, 2022 Filed Aug 5, 2022 00:39 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 16,500 | Not disclosed Strike: $1.05 | Not disclosed |
DisclosureSEC source: 0001209191-22-044464 · doc4.xml · derivative · entry 4 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2031-06-02 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F3 · derivative.exercise_date: These Options are fully vested. Read SEC document |
| August 02, 2022 Filed Aug 5, 2022 00:39 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 16,500 | Not disclosed Strike: $19.70 | Not disclosed |
DisclosureSEC source: 0001209191-22-044464 · doc4.xml · derivative · entry 3 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,500 shares Expires 2031-06-02 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F3 · derivative.exercise_date: These Options are fully vested. Read SEC document |
| August 02, 2022 Filed Aug 5, 2022 00:39 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 16,500 | Not disclosed Strike: $1.05 | Not disclosed |
DisclosureSEC source: 0001209191-22-044464 · doc4.xml · derivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2032-06-02 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F2 · derivative.exercise_date: Reflects an initial grant of 16,500 Options granted on June 3, 2022 that vests as follows: One-twelfth (1/12th) of the shares subject to the Option shall vest on July 2, 2022 and each month thereafter, subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| August 02, 2022 Filed Aug 5, 2022 00:39 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 16,500 | Not disclosed Strike: $1.22 | Not disclosed |
DisclosureSEC source: 0001209191-22-044464 · doc4.xml · derivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,500 shares Expires 2032-06-02 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F2 · derivative.exercise_date: Reflects an initial grant of 16,500 Options granted on June 3, 2022 that vests as follows: One-twelfth (1/12th) of the shares subject to the Option shall vest on July 2, 2022 and each month thereafter, subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 20:21 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 14,846 | $0.00 Strike: $1.17 | $0.00 |
DisclosureSEC source: 0001127602-22-018040 · form4.xml · derivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,846 Underlying: Common Stock · 14,846 shares Expires 2032-06-20 F1 · derivative.exercise_date: The option vests in full on the earlier of June 21, 2023 or the day immediately prior to the company's 2023 annual meeting of shareholders. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 21:11 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantStock Option (right to buy) · Derivative | 16,757 | $0.00 Strike: $55.48 | $0.00 |
DisclosureSEC source: 0001209191-22-036387 · doc4.xml · derivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,757 Underlying: Common Stock · 16,757 shares Expires 2032-06-08 Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:53 UTC | MeiraGTx Holdings plc MGTX · Entity 4734 | GrantRestricted Share Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-006383 · form4-06092022_010625.xml · derivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 15,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit converts into one ordinary share upon vesting. F3 · derivative.exercise_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023. F3 · derivative.expiration_date: The restricted share units shall vest in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:53 UTC | MeiraGTx Holdings plc MGTX · Entity 4734 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $8.25 | $0.00 |
DisclosureSEC source: 0001415889-22-006383 · form4-06092022_010625.xml · derivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 15,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: The option shall vest and become exercisable in a single annual installment upon the earlier of (i) June 7, 2023 or (ii) the day immediately prior to the date of the Issuer's annual meeting of shareholders in 2023. Read SEC document |
| June 03, 2022 Filed Jun 8, 2022 01:21 UTC | Applied Therapeutics, Inc. APLT · Entity 67708 | GrantStock Option (Right to Buy) · Derivative | 16,500 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001209191-22-034931 · doc4.xml · derivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2032-06-02 F1 · derivative.exercise_date: Consists of Options granted to directors under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. One-twelfth (1/12th) of the shares subject to the Option shall vest on July 2, 2022 and each month thereafter, subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| May 20, 2022 Filed May 24, 2022 20:34 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001035443-22-000170 · wf-form4_165342445154816.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 346,026 Read SEC document |
| May 12, 2022 Filed May 13, 2022 21:24 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | SaleCommon Stock | 10,000 | $55.00 | $550,000.00 |
DisclosureSEC source: 0001209191-22-028919 · doc4.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,233 Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 21:30 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | GrantCommon Stock | 24,560 | $0.00 | $0.00 |
DisclosureSEC source: 0001035443-22-000113 · wf-form4_164910782307434.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,526 Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 02:49 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | SaleCommon Stock | 10,000 | $52.89 | $528,900.00 |
DisclosureSEC source: 0001209191-22-017755 · doc4.xml · nonDerivative · entry 4 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Joel S. Marcus and Barbara A. Marcus Family Trust Disclosed balance after: 28,980 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.72 to $53.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| March 08, 2022 Filed Mar 10, 2022 02:49 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | SaleCommon Stock | 5,000 | $52.25 | $261,250.00 |
DisclosureSEC source: 0001209191-22-017755 · doc4.xml · nonDerivative · entry 3 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Joel S. Marcus and Barbara A. Marcus Family Trust Disclosed balance after: 38,980 Read SEC document |
| March 07, 2022 Filed Mar 10, 2022 02:49 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | SaleCommon Stock | 5,000 | $54.52 | $272,600.00 |
DisclosureSEC source: 0001209191-22-017755 · doc4.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the Joel S. Marcus and Barbara A. Marcus Family Trust Disclosed balance after: 43,980 Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 21:52 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | GrantCommon Stock | 16,869 | $0.00 | $0.00 |
DisclosureSEC source: 0001035443-22-000017 · wf-form4_164211074803292.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,966 Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 21:22 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 7,500 | $207.61 | $1,557,075.00 |
DisclosureSEC source: 0001035443-21-000219 · wf-form4_162871692499614.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,097 F1 · price: The shares were sold at prices ranging from $207.40 to $208.00. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 21:02 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 5,000 | $202.63 | $1,013,150.00 |
DisclosureSEC source: 0001035443-21-000215 · wf-form4_162811093999343.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,597 F1 · price: The shares were sold at prices ranging from $202.62 to $202.68. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 29, 2021 Filed Jul 30, 2021 20:42 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 15,000 | $200.00 | $3,000,000.00 |
DisclosureSEC source: 0001035443-21-000203 · wf-form4_162767772654686.xml · nonDerivative · entry 2 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,597 F2 · price: The shares were sold at prices ranging from $200.00 to $200.15. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 28, 2021 Filed Jul 30, 2021 20:42 UTC | ALEXANDRIA REAL ESTATE EQUITIES, INC. ARE · Entity 419 | SaleCommon Stock | 5,000 | $200.02 | $1,000,100.00 |
DisclosureSEC source: 0001035443-21-000203 · wf-form4_162767772654686.xml · nonDerivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,597 F1 · price: The shares were sold at prices ranging from $200.00 to $200.26. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 21, 2021 Filed Jun 22, 2021 20:26 UTC | Intra-Cellular Therapies, Inc. ITCI · Entity 81206 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $43.45 | $0.00 |
DisclosureSEC source: 0001209191-21-042396 · doc4.xml · derivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-20 Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:29 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 14,846 | $0.00 Strike: $10.14 | $0.00 |
DisclosureSEC source: 0001127602-21-020405 · form4.xml · derivative · entry 1 MARCUS JOEL S · CIK 0001216955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,846 Underlying: Common Stock · 14,846 shares Expires 2031-06-16 F1 · derivative.exercise_date: The option vests in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.